about
Pazopanib: approval for soft-tissue sarcoma.ALDH Activity Correlates with Metastatic Potential in Primary Sarcomas of Bone.Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen.Emerging therapies for adult soft tissue sarcoma.Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases.Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case seriesPazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft ModelsAntiangiogenesis therapy: an update after the first decade.Overview of fundamental study of pazopanib in cancer.Novel therapeutic approaches in chondrosarcoma.Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study().Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization fPazopanib: in advanced soft tissue sarcoma.High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage? The Role of Stem and Progenitor Cells in Proliferation, Malignant Degeneration and Therapeutic Resistance.
P2860
Q33885782-D803E9AD-458F-4C87-BD75-BDD392552AC5Q34357258-4DDB4018-FD05-4EAE-AE0B-952ED398893CQ34653360-FFC53CDA-AB3B-419A-B01C-3ECF87B21503Q34659806-2D4513A5-0E8F-4EE0-941B-23978948B168Q34668843-7B7A3B56-3C98-4CB3-A6EC-8D7186497877Q34669352-866A6BFD-D218-484F-8B6E-D3374989BD21Q35028802-3B229658-D701-467B-90D9-3232A88A4490Q38191586-FF9EC343-A11E-4499-B0C8-A41942295B27Q38696525-A3347F3E-DB20-42B9-9EB5-3D61F9322EEEQ38764510-00316347-D74C-411B-9F57-A77EA65F3A0BQ39444949-97D28963-9335-449E-AFAC-BA9FD302B8ABQ41701973-B518C35B-4C1B-4495-9934-694FA4A7D6A9Q42715298-11D39B5D-45B1-4295-BE13-EBCA14704870Q46416035-7FF50151-FA7F-4575-8EE1-537EDAA4E9DEQ48182725-5AF450D5-0020-4153-A0D1-7F9E110C6908
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pazopanib in the treatment of soft tissue sarcoma
@ast
Pazopanib in the treatment of soft tissue sarcoma
@en
Pazopanib in the treatment of soft tissue sarcoma
@nl
type
label
Pazopanib in the treatment of soft tissue sarcoma
@ast
Pazopanib in the treatment of soft tissue sarcoma
@en
Pazopanib in the treatment of soft tissue sarcoma
@nl
prefLabel
Pazopanib in the treatment of soft tissue sarcoma
@ast
Pazopanib in the treatment of soft tissue sarcoma
@en
Pazopanib in the treatment of soft tissue sarcoma
@nl
P2860
P356
P1476
Pazopanib in the treatment of soft tissue sarcoma
@en
P2860
P304
P356
10.1586/ERA.12.41
P407
P577
2012-06-01T00:00:00Z